Researchers at the Jacobs School of Medicine and Biomedical Sciences have developed a new inhalable form of tuberculosis (TB) treatment that could significantly reduce the burden of current therapy.

International non-profit research company IAVI has dosed the first patients in its Phase IIb trial of tuberculosis (TB) vaccine, which, if approved, could be the second to be cleared in more than 100 ...

Sepsis is a leading global cause of hospital deaths, occurring when the body's response to infection damages tissue and ...

Global pharmaceutical major Lupin Limited has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of the investigational drug Telacebec, ...